Comparative Pharmacology
Head-to-head clinical analysis: LIVOSTIN versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVOSTIN versus PROMETH PLAIN.
LIVOSTIN vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category C
Category C
Antihistamine
Antihistamine